James N Topper bought $167k of NAMS
director at NewAmsterdam Pharma Co N.V.. 8,584 shares at an average of $19.50, traded Jun 16, 2025, filed Jun 18, 2025.
Score components
- +15RoleDirector
- +11Trade size$167k at market
- -5Relative to holdingsUnder 1% of holdings (0.3%)
- +4Price context26% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-017693, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 16, 2025 | POpen-market purchase Ordinary Sharesindirect: By Frazier Life Sciences X, L.P. | +8,584 | $19.50 | $167k | 3,022,153 | Jun 18, 2025 |
Related signals
Other insiders at NewAmsterdam Pharma Co N.V. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | NewAmsterdam Pharma Co N.V. | Johannes Jacob Pieter Kastelein Chief Scientific Officer | $1.3M 50,246 shares | -42% | |
| 38Weak | NAMSbuy NewAmsterdam Pharma Co N.V. | Michael H. Davidson Chief Executive Officer | $227k 10,000 shares | +1% | |
| 26Weak | NAMSsell NewAmsterdam Pharma Co N.V. | John W Smither director | $41k 1,600 shares | -15% | |
| 25Weak | NewAmsterdam Pharma Co N.V. | Louise Frederika Kooij Chief Accounting Officer | $5.2M 145,000 shares | -161% | |
| 15Weak | NAMSbuy NewAmsterdam Pharma Co N.V. | James N Topper director | $16k 660 shares | +0% | |
| 45Moderate | NAMSsell NewAmsterdam Pharma Co N.V. | Louise Frederika Kooij Chief Accounting Officer | $3.9M 150,000 shares | -91% | |
| 20Weak | NAMSbuy NewAmsterdam Pharma Co N.V. | James N Topper director | $31k 1,260 shares | +0% | |
| 60Notable | NewAmsterdam Pharma Co N.V. | Louise Frederika Kooij Chief Accounting Officer | $453k 18,073 shares | -55% | |
| 45Moderate | NewAmsterdam Pharma Co N.V. | Louise Frederika Kooij Chief Accounting Officer | $206k 8,269 shares | -36% | |
| 68Notable | NewAmsterdam Pharma Co N.V. | Johannes Jacob Pieter Kastelein Chief Scientific Officer | $2.5M 100,000 shares | -59% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.